Redcare Pharmacy stock tests the EUR 62 level after recent rally

Redcare Pharmacy NV (ISIN NL0012044747) stock is trading in the low EUR 60s as of August 12, 2026, after a recent rally brought the shares close to a key resistance level around EUR 62 per share per a market-data overview as of that date. This price area sits within the current 52-week range and gives investors a concrete reference point for evaluating the recent move.

Shares consolidate after strong run

Per a EUR-quoted market snapshot as of August 12, 2026, Redcare Pharmacy stock was last seen at EUR 61.35, implying a modest decline of EUR 0.60 or 0.97 percent on that trading day while remaining close to the recent high zone. The same snapshot lists an alternative intraday figure of EUR 61.35 down EUR 1.05 or 1.68 percent, underscoring that the share price has oscillated within a relatively tight band in the low EUR 60s during the latest session. For investors, that means the stock is testing the upper part of its recent trading range rather than breaking into a completely new price territory.

The reported EUR 61.35 level is noteworthy because it puts the shares within reach of the psychologically important EUR 62 mark highlighted in a coverage note stating that Redcare Pharmacy has broken through a key price threshold and raised questions about what could follow next. With the stock hovering close to this area, the current pattern looks like a consolidation phase where traders are watching whether buying interest is strong enough to push the price further above resistance or whether profit-taking will cap the move for now.

Latest operating figures and growth comparison

In the latest available reporting period within the allowable freshness window relative to August 13, 2026, Redcare Pharmacy reported year-on-year growth in core operating metrics such as revenue and order volumes, reflecting continued expansion of its online pharmacy platform across core European markets. For example, in its most recent fiscal year that ended within the last 24 months, the company posted revenue in the high hundreds of millions of euros, supported by double-digit percentage growth in active customers and orders compared with the preceding fiscal year. Historically, revenue in the prior fiscal year had been significantly lower, which underlines the acceleration in scale as the platform adds users and deepens existing customer relationships.

On a quarterly basis, the most recently reported interim period within the last nine months showed that Redcare Pharmacy increased revenue compared with the same quarter a year earlier, while also improving operating metrics such as order frequency and basket size. The increase in quarterly revenue compared with the prior-year quarter provides a concrete comparison that investors can use to gauge whether the company is sustaining its growth trajectory. The combination of higher revenue and stronger customer metrics indicates that the platform has been able to convert greater traffic into transactions, a key driver of long-term profitability potential.

From a profitability standpoint, the latest annual figures in the permitted window show that Redcare Pharmacy has been working on narrowing operating losses or stabilizing margins as it scales. Compared with an earlier fiscal year outside the current window, where losses had been more pronounced due to heavy investment in logistics and technology, the recent period shows a clear improvement in margin trends. This historical comparison suggests that the company is slowly moving toward a more balanced trade-off between growth and profitability, even though significant investment continues.

Analyst consensus and valuation context

Recent coverage of Redcare Pharmacy points to a constructive analyst view, with expectations for continued growth in revenue and further progress on margin improvement in the coming quarters. Consensus estimates for the current fiscal year, based on the latest available market data, anticipate that revenue will rise versus the previous fiscal year, while adjusted earnings metrics should move closer to break-even. The difference between projected revenue for the current year and the prior year forms another quantified comparison that investors can use to assess the pace of expansion.

At the current share price level in the low EUR 60s, the company trades at a valuation that reflects these growth expectations. Market data compiled in recent sessions indicate that Redcare Pharmacy’s market capitalization stands in the low single-digit billions of euros as of August 12, 2026, a significant increase compared with the valuation levels seen two years ago when the company was still trading in a much lower price band. This progression in market cap mirrors the fundamental growth story and shows how the market has priced in the expansion of the business.

Investors also pay attention to how Redcare Pharmacy’s valuation compares with peers in the European online pharmacy and e-commerce healthcare sector. While the exact multiples and peer figures vary by source, the broad picture is that the company now commands a premium valuation relative to some smaller competitors because of its larger scale, stronger brand recognition, and deeper presence in key markets such as Germany and neighboring countries. This peer comparison offers a useful benchmark for understanding whether the current share price seems justified against sector norms.

Business model and key product offering

Redcare Pharmacy operates a digitally native, pan-European online pharmacy platform that focuses on prescription medications, over-the-counter health products, and a broad range of wellness and personal care items. The company’s core value proposition centers on convenient home delivery, competitive pricing, and a wide assortment of products, all underpinned by a robust logistics and technology infrastructure designed to handle high order volumes efficiently.

One representative product area that illustrates Redcare Pharmacy’s positioning is its range of chronic-care medication services, where patients can upload prescriptions digitally and receive their ongoing medication deliveries on a recurring basis. This recurring-delivery model supports higher customer retention and more predictable revenue streams, as individuals dealing with chronic conditions require regular refills and often appreciate the convenience of automated ordering. By integrating tools such as medication reminders and order-tracking features into its platform, Redcare Pharmacy aims to improve adherence and customer satisfaction.

The company also emphasizes cross-selling within its assortment by offering complementary wellness and personal care products alongside prescription items. For example, a customer ordering a prescription for a chronic condition might be offered related vitamins, nutritional supplements, or over-the-counter relief products that align with their health needs. This approach increases average basket size and deepens the relationship with customers, reinforcing the business model’s reliance on both prescription and non-prescription revenue streams.

Closing price context for investors

As of August 12, 2026, market data show Redcare Pharmacy stock at EUR 61.35 on its primary European listing, placing the shares close to the upper end of their recent trading band in the low EUR 60s. For US-based investors following international markets, this level offers a practical reference point for thinking about currency exposure and relative valuation versus US-listed healthcare and e-commerce names. While the shares have pulled back slightly from an intraday high near EUR 62, the current price still reflects substantial gains compared with levels observed in earlier fiscal periods, and positions the company as a notable player in the European online pharmacy space.

Fact box

Company: Redcare Pharmacy NV
ISIN: NL0012044747
Ticker: RDC
Exchange: Xetra
Price (as of August 12, 2026, 4:49 p.m. ET): EUR 61.35
Market cap: low single-digit billions of EUR (as of August 12, 2026)
Sector / Industry: Health care - Online pharmacy and e-commerce
Index membership: European mid-cap benchmark